PERRIGO ACQUISITION OF GENTEK OTC BUSINESS will boost the private label company's manufacturing capacity in the cough/cold, antacid, and analgesic areas, Perrigo indicated in a June 28 press release announcing the agreement in principle. The cash deal is expected to close before Aug. 1. "Consumer demand for store brand OTCs has increased significantly in recent years and retailers expect the trend to accelerate in the 1990's," Perrigo President and CEO Michael Jandernoa stated. "This acquisition and recently announced plant expansion will enable Perrigo and their retail customers to satisfy that consumer demand." Gentek is being purchased from NASCO, a holding company based in Nashville, Tennessee. The Gentek acquisition is the first evidence of renewed expansion plans on the part of Perrigo. Perrigo expansion plans had been hampered under Grow Group as a result of the extensive debt taken on by the parent company to acquire the private label manufacturer. The company was acquired from parent Grow Group by a management group last April for $ 61 mil. The purchase of Cincinnati-based Gentek will provide Perrigo with a manufacturing facility and operational staff. Perrigo describes Gentek as a private label manufacturer "specializing in cold remedies, antacids and analgesics." Perrigo is a private label manufacturer of OTC drugs and toiletries with plants in Montego, Michigan, and Greenville, South Carolina, as well as in Allegan, Michigan, where the company is based. For the fiscal year ended June 30, 1987 Perrigo had sales of approximately $ 150 mil.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.
